Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM DISODIUM VERSENATE vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Treatment of lead poisoning (including symptomatic and asymptomatic patients with blood lead levels ≥45 μg/d L in children and ≥70 μg/d L in adults),Off-label: treatment of other heavy metal toxicities (e.g., cadmium, chromium, manganese, nickel)
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Not metabolized; excreted unchanged in urine via glomerular filtration and tubular secretion.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
<5% bound to plasma proteins (albumin)
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
0.2-0.3 L/kg; primarily distributes to extracellular fluid, minimal intracellular penetration
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
IV: 100%; IM: approximately 80-90% (due to local chelation and partial excretion)
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of usual dose; GFR < 10 m L/min: administer 25% of usual dose or consider alternative therapy.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
No specific guidelines available; use with caution and monitor liver function in severe hepatic impairment (Child-Pugh C).
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
25 mg/kg/dose intramuscularly or intravenously every 12 hours for 3-5 days; maximum 1 g/dose.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Consider renal function; elderly patients often require dose reduction based on creatinine clearance; start at lower end of dosing range and monitor for adverse effects.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
This drug is not indicated for the treatment of iron deficiency anemia or hemochromatosis. Do not use in patients with severe renal impairment. Prolonged or excessive use may lead to toxicities including renal failure, convulsions, and cardiac arrhythmias.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Renal toxicity: monitor renal function and urine output; avoid excessive doses. Neurotoxicity: can cause tremors, seizures, and encephalopathy, especially with high doses or rapid infusion. Hydration: maintain adequate hydration to promote urinary excretion. Rebound metal mobilization: may transiently increase tissue metal levels. Hypocalcemia: due to calcium displacement; monitor serum calcium. Cardiac effects: risk of arrhythmias, especially with rapid IV administration.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Absolute: anuria or severe renal failure (creatinine clearance <20 m L/min). Relative: hypersensitivity to edetate salts, pre-existing renal disease, concurrent use with other nephrotoxic drugs.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Avoid excessive intake of calcium and vitamin D supplements during therapy (may reduce chelation efficacy). Maintain adequate hydration with water. No specific food restrictions, but a balanced diet is recommended to prevent deficiencies of essential minerals (zinc, copper) that may be chelated.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fetal zinc/corper deficiency if prolonged use. Avoid unless maternal benefit outweighs risk.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Excreted into breast milk in low amounts; M/P ratio unknown. Caution due to potential for infant mineral chelation. Use only if clearly needed.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No specific dose adjustment required; however, monitor for hypocalcemia and mineral depletion. Increased risk of renal toxicity in pregnancy; ensure adequate hydration.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
Administer deep IM or slow IV infusion (over 2-4 hours) to avoid thrombophlebitis. Monitor urine output and renal function; nephrotoxicity is dose-dependent. Discontinue if oliguria or rising creatinine occurs. For lead encephalopathy, give concurrently with BAL (dimercaprol) to redistribute lead from CNS to blood. Use with caution in patients with pre-existing renal disease, hepatitis, or history of allergic reactions. EDTA can chelate essential metals (zinc, copper) leading to deficiencies during prolonged therapy.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Report any signs of allergic reaction (rash, itching, difficulty breathing) or injection site pain/swelling immediately.,Drink plenty of fluids (unless instructed otherwise) to help flush out lead through urine.,Avoid taking any other medications, supplements, or over-the-counter products without consulting your doctor, as they may affect treatment.,Do not miss scheduled blood and urine tests; they are essential to monitor lead levels and kidney function.,Severe lead poisoning may cause fatigue, headache, abdominal pain; report these symptoms if they worsen.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM DISODIUM VERSENATE vs ALFENTANIL, answered by our medical review team.
CALCIUM DISODIUM VERSENATE is a Chelating Agent that works by Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM DISODIUM VERSENATE and ALFENTANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM DISODIUM VERSENATE is: 1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM DISODIUM VERSENATE and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM DISODIUM VERSENATE is classified as Category C. Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fet. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.